Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 314,020,768
  • Shares Outstanding, K 1,767,140
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • EBIT $ 13,822 M
  • EBITDA $ 22,520 M
  • 60-Month Beta 0.58
  • Price/Sales 5.73
  • Price/Cash Flow 11.14
  • Price/Book 51.29

Options Overview Details

View History
  • Implied Volatility 22.61% ( +0.44%)
  • Historical Volatility 20.31%
  • IV Percentile 72%
  • IV Rank 46.57%
  • IV High 30.36% on 10/29/24
  • IV Low 15.86% on 03/01/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 7,577
  • Volume Avg (30-Day) 18,335
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 399,909
  • Open Int (30-Day) 429,290

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.99
  • Number of Estimates 10
  • High Estimate 3.10
  • Low Estimate 2.96
  • Prior Year 2.79
  • Growth Rate Est. (year over year) +7.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
170.21 +5.16%
on 12/17/24
183.51 -2.46%
on 12/03/24
-2.77 (-1.52%)
since 12/02/24
3-Month
163.81 +9.27%
on 11/19/24
207.32 -13.66%
on 10/31/24
-17.82 (-9.05%)
since 10/02/24
52-Week
153.58 +16.55%
on 05/30/24
207.32 -13.66%
on 10/31/24
+19.18 (+12.00%)
since 01/02/24

Most Recent Stories

More News
5 Large Drug Stocks to Keep An Eye On in the New Year

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services,...

AZN : 66.00 (+0.73%)
JNJ : 144.07 (-0.38%)
LLY : 776.59 (+0.59%)
ABBV : 178.85 (+0.65%)
PFE : 26.64 (+0.41%)
Stock market today: Wall Street indexes lose ground as market closes another record-breaking year

Stock indexes closed mostly lower on Wall Street on the final day of another record-setting year

NFLX : 886.57 (-0.53%)
META : 596.33 (+1.85%)
NVDA : 137.77 (+2.59%)
AAPL : 243.24 (-2.87%)
CVX : 146.89 (+1.42%)
$SPX : 5,862.61 (-0.32%)
SMCI : 30.33 (-0.49%)
JPM : 241.06 (+0.56%)
ABBV : 178.85 (+0.65%)
$IUXX : 20,950.21 (-0.29%)
DAL : 59.13 (-2.26%)
MSFT : 418.05 (-0.82%)
3 Highest-Yielding Dividend Kings To Buy Today

Start your New Year early by exploring high-yield Dividend Kings with decades of growth, top analyst ratings, and attractive yields for long-term investors.

KO : 61.84 (-0.67%)
FRT : 109.01 (-1.66%)
ABBV : 178.85 (+0.65%)
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Immunotherapy is revolutionizing oncology by harnessing the power of the immune system to fight cancer...

ONCY : 0.9150 (+0.13%)
AUTL : 2.63 (+11.91%)
IOVA : 7.76 (+4.86%)
ABBV : 178.85 (+0.65%)
ONC.TO : 1.33 (unch)
IBRX : 2.57 (+0.39%)
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

ONCY : 0.9150 (+0.13%)
AZN : 66.00 (+0.73%)
ABBV : 178.85 (+0.65%)
ONC.TO : 1.33 (unch)
GSK : 33.89 (+0.21%)
CRDF : 4.30 (-0.92%)
The Smartest Dividend Stocks to Buy With $1,000 Right Now

If you're looking for attractive dividend-paying stocks, that's a smart move. If you're not, perhaps reconsider -- because:

T : 22.88 (+0.48%)
JNJ : 144.07 (-0.38%)
KVUE : 21.25 (-0.47%)
ABBV : 178.85 (+0.65%)
Introducing the "Dividend Seven" Stocks

In this podcast, Motley Fool analysts Matt Argersinger and Anthony Schiavone join host Mary Long to discuss:

BLK : 1,017.13 (-0.78%)
META : 596.33 (+1.85%)
NVDA : 137.77 (+2.59%)
C : 70.07 (-0.45%)
BAC : 44.26 (+0.71%)
KO : 61.84 (-0.67%)
JPM : 241.06 (+0.56%)
PLD : 104.38 (-1.25%)
ABBV : 178.85 (+0.65%)
GS : 576.08 (+0.60%)
MCD : 292.80 (+1.00%)
HSY : 168.33 (-0.60%)
Is AbbVie Stock a Buy?

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to offer to...

ABBV : 178.85 (+0.65%)
2 Excellent Dividend Stocks to Buy on the Dip

AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common. They are both leading drugmakers and have strong dividend track records. Both also recently saw their shares fall significantly in one...

ABBV : 178.85 (+0.65%)
AMGN : 259.31 (-0.51%)
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid...

ABBV : 178.85 (+0.65%)
PFE : 26.64 (+0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 180.31
2nd Resistance Point 179.07
1st Resistance Point 178.39
Last Price 179.05
1st Support Level 176.47
2nd Support Level 175.23
3rd Support Level 174.55

See More

52-Week High 207.32
Fibonacci 61.8% 186.79
Fibonacci 50% 180.45
Last Price 179.05
Fibonacci 38.2% 174.11
52-Week Low 153.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar